| 13.85 -3.97 (-22.28%) | 06-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 33.84 | 1-year : | 39.53 |
| Resists | First : | 28.97 | Second : | 33.84 |
| Pivot price | 17.17 |
|||
| Supports | First : | 17.73 | Second : | 10.77 |
| MAs | MA(5) : | 23.85 |
MA(20) : | 17.35 |
| MA(100) : | 23.84 |
MA(250) : | 15.05 |
|
| MACD | MACD : | 0.8 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 72.7 |
D(3) : | 76 |
| RSI | RSI(14): 59.8 |
|||
| 52-week | High : | 36.75 | Low : | 6.32 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SNSE ] has closed below upper band by 21.7%. Bollinger Bands are 62.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 27.01 - 27.15 | 27.15 - 27.24 |
| Low: | 22.13 - 22.29 | 22.29 - 22.39 |
| Close: | 22.65 - 22.88 | 22.88 - 23.03 |
Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform. This immunotherapy leverages bacteriophages to orchestrate a precise and robust innate and adaptive immune response. They also employ the Tumor Microenvironment Activated Biologics (TMAB) platform. This system is engineered to unleash T-cells' anti-tumor capabilities, utilizing human monoclonal antibodies specifically designed to operate within the tumor's immediate environment and target key immune checkpoints or other crucial signaling pathways. Sensei Biotherapeutics' pipeline features SNS-101, a monoclonal antibody developed for cancer therapy, and SNS-401-NG, an ImmunoPhage vaccine engineered to target a range of tumor antigens. Furthermore, they collaborate with The University of Washington on the research and development of a vaccine for Merkel cell carcinoma. Established in 1999, originally as Panacea Pharmaceuticals, Inc., Sensei Biotherapeutics maintains its headquarters in Rockville, Maryland.
Sun, 20 Sep 2026
Sensei Biotherapeutics stock holds recent gains after volatile year - AD HOC NEWS
Mon, 17 Aug 2026
Sensei Biotherapeutics (SNSE) Stock Holds Ground at $13.85 With Support and Resistance in Focus - Call Spread Alert - siam.in
Mon, 17 Aug 2026
Sensei Biotherapeutics (SNSE) Stock Holds Ground at $13.85 With Support and Resistance in Focus - Wave Alternation - careplusvn.com
Wed, 29 Jul 2026
Sensei Biotherapeutics (SNSE) Holds Steady at $13.85 as Biotech Sector Awaits Catalysts - IV Spike - careplusvn.com
Tue, 16 Jun 2026
FTH - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 28.2 (%) |
| Held by Institutions | 153 (%) |
| Shares Short | 798 (K) |
| Shares Short P.Month | 834 (K) |
| EPS | -142.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -102.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -95.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -138.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -24 (M) |
| Levered Free Cash Flow | -92 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | -0.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|